Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Simulations Plus ( (SLP) ).
On January 8, 2026, Simulations Plus reported fiscal first-quarter 2026 results for the period ended November 30, 2025, showing a 3% year-over-year decline in total revenue to $18.4 million, as a 17% drop in software revenue to $8.9 million was offset by a 16% increase in services revenue to $9.5 million, which for the quarter became the larger contributor to sales. Despite lower adjusted EBITDA and adjusted net income versus the prior year, the company improved gross margin to 59%, increased GAAP net income to $0.7 million, and met its revenue guidance, while management highlighted strong services performance, favorable client funding conditions, and solid bookings in both software and services as support for reaffirming full-year 2026 guidance, including projected revenue of $79 million to $82 million and an adjusted EBITDA margin of 26% to 30%.
The most recent analyst rating on (SLP) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Simulations Plus stock, see the SLP Stock Forecast page.
Spark’s Take on SLP Stock
According to Spark, TipRanks’ AI Analyst, SLP is a Neutral.
Simulations Plus has a mixed outlook. The financial performance is challenged by declining revenue and profitability, but the balance sheet and cash flow remain strong. Technical analysis shows positive momentum, though valuation concerns persist due to negative earnings. The earnings call highlights strategic growth initiatives but also notes significant challenges, leading to a cautious overall score.
To see Spark’s full report on SLP stock, click here.
More about Simulations Plus
Simulations Plus, Inc. is a global leader in model-informed and AI-accelerated drug development, providing science-based software and consulting services that help biopharmaceutical companies and other clients accelerate the discovery, development, and commercialization of pharmaceuticals and related products.
Average Trading Volume: 381,041
Technical Sentiment Signal: Sell
Current Market Cap: $388.2M
Find detailed analytics on SLP stock on TipRanks’ Stock Analysis page.